Tigenix NV has thrown in the towel on its efforts to obtain broad reimbursement in Europe for its Chondrocelect autologous cell therapy for regenerating cartilage in the knee and has signed over marketing and distribution rights to Swedish Orphan Biovitrum AB (Sobi) in return for double-digit sales royalties.